Drug Trial Radar · NCT07448597
Progesterone Preeclampsia
Last checked: Nov 20, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
642
Planned (sponsor's estimate)
Start
Aug 13, 2026
Primary completion
Aug 1, 2028
Study completion Aug 1, 2028
Sponsor
- Lead sponsor
- Medical University of South CarolinaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This randomized controlled trial evaluates whether nightly vaginal micronized progesterone (400 mg) initiated before 12 weeks' gestation reduces the incidence of preeclampsia in low-risk pregnant individuals. Participants will be randomly assigned (1:1) to receive either vaginal progesterone through 16 weeks' gestation or routine prenatal care without progesterone. Maternal and neonatal outcomes-including development of preeclampsia, obstetric complications, gestational diabetes, preterm birth, and neonatal morbidity-will be collected via chart review. The study aims to determine whether early progesterone supplementation decreases the risk of preeclampsia.
Conditions
- Preeclampsia
- Hypertensive Disorder of Pregnancy
Interventions
Progesterone supplementationDrug
Patients in the progesterone arm will be randomized to receive progesterone supplementation while the control arm will not receive any additional intervention.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Development of preeclampsiaTime frame: Antenatally and up to 6 weeks postpartum
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Medical University of South Carolina
Charleston, South Carolina · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.